For research use only
| Cat No. | ABC-TC0712 |
| Product Type | Mouse Breast Cancer Cell Lines |
| Species | Mouse – BALB/C |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | MTV TM-011, MTV-TM-011, MT V/TM-011 |
MTV-L/CL2 mouse mammary tumor cells fused with thymocyte and macrophages, it metastasizes to the lung massively and causes cachexia
MTV/TM‑011 is a mouse mammary carcinoma hybrid cell line generated by fusing BALB/c-derived MTV-L/CL2 tumor cells with thymocytes and macrophages. These well-differentiated carcinoma cells exhibit epithelial-like morphology in adherent culture and metastasize aggressively to the lungs, causing cachexia in syngeneic hosts. Cells maintain stable adherent growth. MTV/TM‑011 shows characteristics of genomic instability which is typical for fusion-derived tumor hybrids. In vivo, cells form primary mammary tumors and undergo massive lung metastasis in BALB/c mice. This line is ideal for modeling tumor progression and metastasis biology. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from mycoplasma, fungi, yeast, and bacteria.
| Product Code | MTV TM-011, MTV-TM-011, MT V/TM-011 |
| Species | Mouse – BALB/C |
| Cat.No | ABC-TC0712 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Breast Cancer Cell Lines |
MTV/TM‑011 is a powerful in vivo and in vitro model for studying metastatic breast cancer, tumor–immune cell interactions, and cancer cachexia. Its robust metastasis to the lung enables evaluation of anti-metastatic therapies, invasion and migration assays, and cachexia-targeting interventions. In vitro, the cell line supports drug screening, tumor microenvironment studies, and assays of cell adhesion and epithelial dynamics. Due to its origin from fusion with immune cells, MTV/TM‑011 is also useful for exploring hybrid-cell genomic instability and the role of immune components in tumor progression.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
